# US 2021/0275649 A1 · Compositions and methods for preventing tumors and cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275649 A1
- Document ID: US20210275649A1
- Status: Published application
- Kind: A1
- Application number: 17/148,159
- Filed: 2021-01-13
- Published: 2021-09-09
- Earliest claimed: 2017-06-15
- Assignees: Cancer Advances Inc.
- Applicants: Cancer Advances Inc.
- Inventors: Lynda Sutton; Jill P. Smith; Allen Cato; Teresa Phillips
- Web page: https://patentgrep.com/patent/US20210275649A1

## CPC

- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/001144: {Hormones, e.g. calcitonin}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61P 35/00: Antineoplastic agents
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2039/6081: {Albumin; Keyhole limpet haemocyanin [KLH]}
- A61K 2039/627: {characterised by the linker}
- A61K 2039/852: {Pancreas}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are methods for preventing initiation and/or progression of gastrin-associated tumors and/or cancers in subjects. In some embodiments, the methods relate to administering compositions that gastrin immunogens to subjects. Also provided are methods for inhibiting development of gastrin-associated precancerous lesions, methods for preventing formation of fibrosis associated with a tumor and/or a cancer, uses of compositions that include a gastrin immunogen to prevent initiation and/or development of a gastrin-associated tumor or cancer and/or for preparing medicaments therefor, and compositions for use in preventing initiation and/or development of gastrin-associated tumors and/or cancers and/or precancerous lesions thereof.

## Claims

### Claim 1

A method for preventing initiation or progression of a gastrin-associated tumor or cancer in a subject, the method comprising:
(a) providing a subject at risk for developing a gastrin-associated tumor or cancer; and
(b) administering to the subject a composition comprising a gastrin immunogen, wherein the gastrin immunogen induces an anti-gastrin humor and/or cellular immune response in the subject sufficient to prevent initiation or progression of a gastrin-associated tumor or cancer in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the gastrin immunogen comprises a gastrin peptide, optionally a gastrin peptide comprising, consisting essentially of, or consisting of an amino acid sequence selected from the group consisting of EGPWLEEEEE (SEQ ID NO: 1), EGPWLEEEE (SEQ ID NO: 2), EGPWLEEEEEAY (SEQ ID NO: 3), and EGPWLEEEEEAYGWMDF (SEQ ID NO: 4).

### Claim 3 (depends on 2)

The method of claim 2, wherein the gastrin peptide is conjugated to an immunogenic carrier, optionally via a linker.

### Claim 4 (depends on 3)

The method of claim 3, wherein the immunogenic carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, keyhole limpet hemocyanin, and bovine serum albumin.

### Claim 5 (depends on 4)

The method of claim 4, wherein the linker comprises a ε-maleimido caproic acid N-hydroxysuccinamide ester.

### Claim 6 (depends on 3)

The method of claim 3, wherein the linker and the gastrin peptide are separated by an amino acid spacer, optionally wherein the amino acid spacer is between 1 and 10 amino acids in length, further optionally wherein the amino acid spacer is 7 amino acids in length.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition further comprises an adjuvant, optionally an oil-based adjuvant.

### Claim 8 (depends on 1)

The method of claim 1, wherein the gastrin-associated tumor and/or cancer is pancreatic cancer.

### Claim 9 (depends on 8)

The method of claim 8, wherein the composition induces a reduction in and/or prevents the development of fibrosis associated with the pancreatic cancer.

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition is administered in a dose selected from the group consisting of about 50 μg to about 1000 μg, about 50 μg to about 500 μg, about 100 μg to about 1000 μg, about 200 μg to about 1000 μg, and about 250 μg to about 500 μg, and optionally wherein the dose is repeated once, twice, or three times, optionally wherein the second dose is administered 1 week after the first dose and the third dose, if administered, is administered 1 or 2 weeks after the second dose.

### Claim 11

A method for inhibiting development of a gastrin-associated precancerous lesion in a subject, the method comprising:
(a) providing a subject at risk for developing a gastrin-associated precancerous lesion; and
(b) administering to the subject a composition comprising a gastrin immunogen, wherein the gastrin immunogen inhibits development of the gastrin-associated precancerous lesion in the subject.

### Claim 12 (depends on 11)

The method of claim 11, wherein the gastrin immunogen comprises a gastrin peptide.

### Claim 13 (depends on 12)

The method of claim 12, wherein the gastrin peptide comprises, consists essentially of, or consists of an amino acid sequence selected from the group consisting of EGPWLEEEEE (SEQ ID NO: 1), EGPWLEEEE (SEQ ID NO: 2), EGPWLEEEEEAY (SEQ ID NO: 3), and EGPWLEEEEEAYGWMDF (SEQ ID NO: 4).

### Claim 14 (depends on 12)

The method of claim 12, wherein the gastrin peptide is conjugated to an immunogenic carrier, optionally via a linker.

### Claim 15 (depends on 14)

The method of claim 14, wherein the immunogenic carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, keyhole limpet hemocyanin, and bovine serum albumin.

### Claim 16 (depends on 14)

The method of claim 14, wherein the linker comprises a ε-maleimido caproic acid N-hydroxysuccinamide ester.

### Claim 17 (depends on 14)

The method of claim 14, wherein the linker and the gastrin peptide are separated by an amino acid spacer, optionally wherein the amino acid spacer is between 1 and 10 amino acids in length, further optionally wherein the amino acid spacer is 7 amino acids in length.

### Claim 18 (depends on 11)

The method of claim 11, wherein the composition further comprises an adjuvant, optionally an oil-based adjuvant.

### Claim 19 (depends on 11)

The method of claim 11, wherein the gastrin-associated tumor and/or cancer is pancreatic cancer.

### Claim 20 (depends on 11)

The method of claim 11, wherein the composition induces a reduction in and/or prevents the development of fibrosis associated with the pancreatic cancer and the gastrin-associated precancerous lesion comprises a pancreatic intraepithelial neoplasia (PanINs).

### Claim 21 (depends on 11)

The method of claim 11, wherein the composition is administered in a dose selected from the group consisting of about 50 μg to about 1000 μg, about 50 μg to about 500 μg, about 100 μg to about 1000 μg, about 200 μg to about 1000 μg, and about 250 μg to about 500 μg, and optionally wherein the dose is repeated once, twice, or three times, optionally wherein the second dose is administered 1 week after the first dose and the third dose, if administered, is administered 1 or 2 weeks after the second dose.

### Claim 22

A method for preventing formation of fibrosis associated with a tumor and/or a cancer, the method comprising contacting cells of the tumor and/or the cancer with a composition that comprises, consists essentially of, or consists of an agent that directly or indirectly inhibits one or more biological activities of gastrin in the tumor and/or cancer.

### Claim 23 (depends on 22)

The method of claim 22, wherein the agent induces a humoral immune response against a gastrin peptide, optionally wherein the agent comprises a gastrin peptide that induces production of a neutralizing anti-gastrin antibody in the subject.

### Claim 24 (depends on 23)

The method of claim 23, wherein the neutralizing anti-gastrin antibody binds to an epitope that is present within the amino acid sequence EGPWLEEEEE (SEQ ID NO: 1), EGPWLEEEE (SEQ ID NO: 2), EGPWLEEEEEAY (SEQ ID NO: 3), or EGPWLEEEEEAYGWMDF (SEQ ID NO: 4).

### Claim 25 (depends on 22)

The method of claim 22, wherein the agent comprises a gastrin peptide that induces production of neutralizing anti-gastrin antibodies conjugated to an immunogenic carrier.

### Claim 26 (depends on 25)

The method of claim 25, wherein the gastrin peptide comprises, consists essentially of, or consists of an amino acid sequence selected from the group consisting of EGPWLEEEEE (SEQ ID NO: 1), EGPWLEEEE (SEQ ID NO: 2), EGPWLEEEEEAY (SEQ ID NO: 3), and EGPWLEEEEEAYGWMDF (SEQ ID NO: 4).

### Claim 27 (depends on 25)

The method of claim 25, wherein the immunogenic carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, keyhole limpet hemocyanin, and bovine serum albumin.

### Claim 28 (depends on 25)

The method of claim 25, wherein the gastrin peptide is conjugated to the immunogenic carrier via a linker.

### Claim 29 (depends on 28)

The method of claim 28, wherein the linker comprises a ε-maleimido caproic acid N-hydroxysuccinamide ester.

### Claim 30 (depends on 28)

The method of claim 28, wherein the linker and the gastrin peptide are separated by an amino acid spacer, optionally wherein the amino acid spacer is between 1 and 10 amino acids in length, further optionally wherein the amino acid spacer is 7 amino acids in length.

### Claim 31 (depends on 22)

The method of claim 22, wherein the composition further comprises an adjuvant, optionally an oil-based adjuvant.

### Claim 32 (depends on 22)

The method of claim 22, wherein the tumor and/or cancer is pancreatic cancer.

### Claim at position 33

33-42. (canceled)
